Synthetic Lethal Therapy for KRAS Mutant Non-small-cell Lung Carcinoma with Nanoparticle-mediated CDK4 siRNA Delivery

The KRAS mutation is present in ~20% of lung cancers and has not yet been effectively targeted for therapy. This mutation is associated with a poor prognosis in non-small-cell lung carcinomas (NSCLCs) and confers resistance to standard anticancer treatment drugs, including epidermal growth factor re...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Mao, Cheng-Qiong, Xiong, Meng-Hua, Liu, Yang, Shen, Song, Du, Xiao-Jiao, Yang, Xian-Zhu, Dou, Shuang, Zhang, Pei-Zhuo, Wang, Jun
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2014
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4015238/
https://ncbi.nlm.nih.gov/pubmed/24496383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2014.18
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg